CALL - SPRINTER OPEN END - NOVO-NORDISK B | Market Closed - Bid/Ask 09:44:28 26/06/2024 BST | After market 20:32:31 | |||
| 24.73 EUR | +4.08% |
|
24.39 | -1.37% |
| Current month | +8.69% | ||
| 1 month | +6.55% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 26/06/24 | 24.73 | +4.08% |
| 25/06/24 | 23.76 | -0.29% |
| 24/06/24 | 23.83 | +0.80% |
| 20/06/24 | 23.64 | +0.17% |
| 19/06/24 | 23.6 | -0.08% |
Delayed Quote Börse Stuttgart
Last update June 26, 2024 at 09:44 am
More quotesStatic data
| Product type | Knock-Out ohne Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Vontobel
|
| WKN | VN5PGC |
| ISIN | DE000VN5PGC7 |
| Date issued | 21/11/2016 |
| Strike | 98.47 kr |
| Maturity | Unlimited |
| Parity | 5 : 1 |
| Emission price | 0.3 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 24.73 € |
|---|---|
| Lowest since issue | 0.23 € |
| Spread | 0.14 € |
| Spread % | 0.57% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
1,028
DKK
Average target price
938.1
DKK
Spread / Average Target
-8.74%
- Stock Market
- Certificates
- Certificat
